Clovis’s Rubraca Is First PARP For Prostate Cancer, But AZ’s Lynparza Coming Soon
Executive Summary
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
You may also be interested in...
Synnovation Aims At Precision Oncology With $102m In Venture Backing
Third Rock Ventures is leading a $102m series A for Synnovation, a cancer-focused biotech led by several former Incyte scientists. The new firm wants to develop best-in-class drugs against validated targets.
Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
AZ's Lynparza Shines Again In Prostate Cancer Study
With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.